Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
Frank
J A
JA
Laboratory of Diagnostic Radiology Research, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD, USA.
Bash
C
C
Stone
L
L
Petrella
J
J
Maloni
H
H
McFarland
H
H
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D001921:Brain / Q000187:drug effects / Q000473:pathology; D003287:Contrast Media; D004338:Drug Combinations; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008536:Meglumine; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000473:pathology; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives*
D000276:Adjuvants, Immunologic; D003287:Contrast Media; D004338:Drug Combinations; D009942:Organometallic Compounds; D000068576:Interferon beta-1b; D008536:Meglumine; D016899:Interferon-beta; D004369:Pentetic Acid; D019786:Gadolinium DTPA; D000068556:Interferon beta-1a